Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Headache Center

Treatment for All Types of Headache Disorders

The GW Medical Faculty Associates Headache Center was established in July 2015 with the mission to provide the Washington, D.C. area with expert headache services. We treat patients with all types of headache disorders, using a multi-faceted and personalized approach. In addition, we engage in research to advance the understanding of headaches and develop new/improved treatments.

To learn more about our mission and approach to headache management, please see our Mission Statement.

Meet Our Providers:

New Patients

Welcome to The GW Medical Faculty Associates Headache Center! We are excited to work with you to (1) diagnose your underlying headache disorder(s), (2) understand the impact your headaches have on your daily life and (3) develop an individualized treatment plan to improve the frequency and severity of your headaches, thus limiting/eliminating disability. We are devoted to empowering our patients, by emphasizing their active role in the management of their headache disorder(s).

Headaches can be disabling and complex. We use a multidisciplinary approach to achieve the best results. This can include:

  • Patient education
  • Physical therapy
  • Biofeedback and relaxation techniques
  • Psychotherapy
  • Medications to manage pain
  • Procedures (Botox, nerve blocks) to manage pain
  • Access to new treatments via participation in research protocols
  • Access to acute IV migraine therapy in our Headache Rescue Room

To make your first visit as efficient as possible, please fill out and bring the Patient Questionnaire to your first visit. If you have a referral, please bring it with you to your appointment. We recommend arriving at least 15 minutes prior to your scheduled appointment so we can maximize the amount of time we spend with you during your visit.

We believe in a strong patient-provider alliance, where we work as a team to regain control over your headaches. We look forward to working with you to alleviate your pain and improve your quality of life.

Conveniently Located

Clinical Trials

  • Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)
    This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS
  • Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))
    The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.
  • Sleep for Stroke Management And Recovery Trial (SleepSmart)
    Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.
  • Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)
    This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention
  • A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)
    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
  • A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)
    This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.
  • A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)
    Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)
    Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
  • A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)
    This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX
  • A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)
    This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects
  • A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)
    Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)